Vaxfactin (TVDV) Toxicity Study

The Naval Medical Logistics Command intends to negotiate, on a sole source basis (IAW FAR 13), with Vical, Inc. 10390 Pacific Center Court, San Diego, CA 92121, as the only source that can provide Vaxfectin, a proprietary adjuvant covered under US and International patent law, which is required to perform this study.The toxicity study is a continuation of the work Vical already has in progress under a sole source contract, N00189-08-P-Z519, to produce Tetravalent Dengue Vaccine (TVDV), another required part of the intended study. This acquisition is being conducted under commercial acquisition procedures (IAW FAR 12). The intended procurement will be classified under North American Industry Classification System (NAICS) 325414. This notice of intent is not a request for competitive proposals and no solicitation document exists for this requirement. However, parties interested in responding to this notice will need to submit technical data sufficient to determine capability in providing the same product. All capability statements received within 10 days after publication of this synopsis will be considered by the Government. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Capability statements shall be submitted by email only as a MS Word or Adobe PDF attachment to Douglas Nathan at [email protected]. Statements are due by COB 14 August 2009. No phone calls accepted.